William Tillett, MD, PhD

Royal National Hospital for rheumatic diseases
Bath, United Kingdom

Clinical academic rheumatologist at the Royal National Hospital for Rheumatic Diseases (RNHRD). The aim of my research is the prevention of disability in inflammatory arthritis through earlier detection, stratified intervention, more accurate and meaningful disease measurement. A major focus of my work is improving patient involvement in arthritis research.

Disclosure information not submitted.

Presentation(s):

0380: Changes in Disease Activity and Patient-Reported Outcomes in Psoriatic Arthritis Patients Treated with Ixekizumab in a Real-World US Cohort
Saturday, November 12, 2022
1:00 PM – 3:00 PM Eastern Time
0391: Dynamics of Nail Psoriasis with Guselkumab Treatment and Withdrawal in Association with Skin Response and Patient-reported Outcomes Based on a post Hoc Analysis of Clinical Trial Data
Saturday, November 12, 2022
1:00 PM – 3:00 PM Eastern Time
2131: Minimal Disease Activity Response Patterns in Bio-Naïve Patients Treated with Guselkumab: A Machine Learning Analysis
Sunday, November 13, 2022
9:30 AM – 9:35 AM Eastern Time
2142: Strong Correlation Between Short- vs Long-form Composite Measures of Psoriatic Arthritis Disease Activity in a TNFi-IR Population Treated with Guselkumab: Data from the Phase 3b COSMOS Trial
Sunday, November 13, 2022
9:35 AM – 9:40 AM Eastern Time
1015: Predictors of Nail Response with Guselkumab: A Post Hoc Analysis of the VOYAGE 2 Clinical Trial
Sunday, November 13, 2022
9:00 AM – 10:30 AM Eastern Time
1017: Minimal Important Difference (MID), Minimal Detectable Change (MDC), and Disease Activity Thresholds for Two Novel Composite Instruments (3VAS, 4VAS) in Patients with Psoriatic Arthritis: Pooled Analysis of Three Phase 3 Studies
Sunday, November 13, 2022
9:00 AM – 10:30 AM Eastern Time
1268: Evaluating Numeric Rating Scale Versions of the 3 and 4 Visual Analog Scale (3/4-VAS) Composite Measures in Patients with Active Psoriatic Arthritis from the SELECT-PsA Program
Sunday, November 13, 2022
1:00 PM – 3:00 PM Eastern Time
1613: Diagnostic Delay and Less Intensive Therapy for People with Psoriatic Arthritis Compared with Rheumatoid Arthritis: A Nested Matched Cohort Study from Within the UK National Early Inflammatory Arthritis Audit
Sunday, November 13, 2022
5:30 PM – 5:40 PM Eastern Time
2131: Minimal Disease Activity Response Patterns in Bio-Naïve Patients Treated with Guselkumab: A Machine Learning Analysis
Monday, November 14, 2022
1:00 PM – 3:00 PM Eastern Time
2142: Strong Correlation Between Short- vs Long-form Composite Measures of Psoriatic Arthritis Disease Activity in a TNFi-IR Population Treated with Guselkumab: Data from the Phase 3b COSMOS Trial
Monday, November 14, 2022
1:00 PM – 3:00 PM Eastern Time